NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today the exercise in full by the underwriters of an over-allotment option to purchase 235,109 shares from the Company and 102,391 shares from a selling stockholder in connection with its follow-on stock offering that priced on December 14, 2006. Including the over-allotment shares, the Company is expected to receive net proceeds of approximately $51.4 million from the sale of its common stock, and it will not receive any proceeds from the sale of shares by the selling stockholder.
